The UK and US have forged a major commercial pact that will keep zero tariffs on British drug products entering the US market.
Key Provisions of the Deal
As part of the deal, the UK has committed to increase expenditure on medicines through the public health system. This move guarantees that duties on these crucial products will be held at zero for a timeframe of 36 months.
This agreement follows earlier warnings to dramatically increase duties on branded pharmaceutical products, with potential rates mentioned reaching one hundred percent.
"This agreement between the Britain strengthens the worldwide climate for new treatments and introduces long-overdue balance to U.S.–U.K. pharmaceutical trade," an announcement noted.
Commercial Significance
Drugs represent one of the UK's biggest export categories to the America, which is by far the biggest market for large UK drugmakers.
Trade data indicate that in the one-year period leading up to last September, the UK sold pharmaceutical products valued at £11.1bn to the US. This figure accounted for 17.4% of total UK exports in that span.
"This agreement secures jobs, increases investment and facilitates the UK to become a international leader for medical research," a government official stated.
Specific British Pledges
The pact involves several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise total NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at 15%. Last year, rebates were more than 20%.
Broader Context
This agreement comes amid a long-running tension between the drug companies and the British authorities over medicine costs and regulatory access.
These tensions were intensified by claims that US patients were charged several times more for the same drugs than people in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been paused or scrapped, while substantial expansions have been pledged toward US facilities.
A senior figure acknowledged that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a share of its total funding over the previous ten-year period.
